Synthetic peptide amides and dimers thereof
The invention relates to synthetic peptide amide ligands of the kappa opioid receptor and particularly to agonists of the kappa opioid receptor that exhibit low P 450 CYP inhibition and low penetration into the brain. The synthetic peptide amides of the invention conform to the structure: The compounds are useful in the prophylaxis and treatment of pain and inflammation associated with a variety of diseases and conditions.
1. A method of treating, inhibiting or preventing kappa opioid receptor associated pain, or of inhibiting or treating kappa opioid receptor associated pancreatitis or pruritis in a mammal, the method comprising administering to the mammal a composition comprising an effective amount of a synthetic peptide amide having the formula:
or a stereoisomer, mixture of stereoisomers, pharmaceutically acceptable salt, hydrate, acid salt hydrate, or N-oxide thereof,
wherein
each Xaa 1 is independently selected from the group consisting of (A)(A′)D-Phe, (A)(A′)(α-Me)D-Phe, D-Tyr, D-Tic, D-tert-leucine, D-neopentylglycine, D-phenylglycine, D-homophenylalanine, and β-(E)D-Ala, wherein each (A) and each (A′) are phenyl ring substituents independently selected from the group consisting of —H, —F, —Cl, —NO 2 , —CH 3 , —CF 3 , —CN and —CONH 2 , and wherein each (E) is independently selected from the group consisting of cyclobutyl, cyclopentyl, cyclohexyl, pyridyl, thienyl and thiazolyl;
each Xaa 2 is independently selected from the group consisting of (A)(A′)D-Phe, (A)(A′)(α-Me)D-Phe, D-1Nal, D-2Nal, D-Tyr, (E)D-Ala, and D-Trp;
each Xaa 3 is independently selected from the group consisting of D-Nle, D-Phe, (E)D-Ala, D-Leu, (α-Me)D-Leu, D-Hle, D-Val, and D-Met;
each Xaa 4 is independently selected from the group consisting of (B) 2 D-Arg, (B) 2 D-Nar, (B) 2 D-Har, ξ-(B)D-Hlys, D-Dap, ε-(B)D-Lys, ε-(B) 2 -D-Lys, D-Amf, amidino-D-Amf, γ-(B) 2 D-Dbu, δ-(B) 2 α-(B′)D-Orn, D-2-amino-3(4-piperidyl)propionic acid, D-2-amino-3(2-aminopyrrolidyl)propionic acid, D-α-amino-β-amidino-propionic acid, α-amino-4-piperidineacetic acid, cis-α,4-diaminocyclohexane acetic acid, trans-α,4-diaminocyclohexaneacetic acid, cis-α-amino-4-methyl-aminocyclo-hexane acetic acid, trans-α-amino-4-methylaminocyclohexane acetic acid, α-amino-1-amidino-4-piperidineacetic acid, cis-α-amino-4-guanidino-cyclohexane acetic acid, and trans-α-amino-4-guanidinocyclohexane acetic acid, wherein each (B) is independently selected from the group consisting of —H and C 1 -C 4 alkyl, and (B′) is —H or (α-Me), and p is zero or 1;
G is selected from one of the following moieties:
(i) G is
wherein
q is zero or 1;
r is zero or 1;
s is zero or 1;
p and t are each independently zero or 1, provided that at least one of q, r, s and t is 1;
and wherein either
A. (i) L is a linker selected from the group consisting of ε-D-Lys, ε-Lys, δ-D-Orn, ε-Orn, γ-aminobutyric acid, 8-aminooctanoic acid, 11-amino-undecanoic acid, 8-amino-3,6-dioxaoctanoic acid, 4-amino-4-carboxylic piperidine and (D-Lys-GlyLactam) 2 , and
(ii) the moieties Xaa 1 -Xaa 2 -Xaa 3 -(Xaa 4 ) p and (Xaa 1 ) q -(Xaa 2 ) r -(Xaa 3 ) s -(Xaa 4 ) t are different from one another, or
B. L is a linker selected from the group consisting of γ-aminobutyric acid, 8-aminooctanoic acid, 11-amino-undecanoic acid, 8-amino-3,6-dioxaoctanoic acid, 4-amino-4-carboxylic piperidine and (D-Lys-Gly Lactam) 2 ,
and
(ii) G is
wherein p is 1;
and
the moiety
is an optionally substituted 6 or 7-membered heterocyclic ring moiety wherein Y is C or N and Z is C, N, O, S, SO, or SO 2 ; provided that Y and Z are separated by at least two ring atoms; and provided further that when such ring moiety is aromatic, then Y is C;
wherein W is selected from the group consisting of:
null, provided that when W is null, Y is N;
—NH—(CH 2 ) b — with b equal to zero, 1, 2, 3, 4, 5, or 6; and
—NH—(CH 2 ) c —O— with c equal to 2, or 3;
wherein V is C 1 -C 6 alkyl, and e is zero or 1, wherein when e is zero, then V is null and, R 1 and R 2 are directly bonded to the same or different ring atoms;
wherein
(a) R 1 is —H, —OH, halo, CF 3 , —NH 2 , —COOH, C 1 -C 6 alkyl, amidino, C 1 -C 6 alkyl-substituted amidino, aryl, optionally substituted heterocyclyl, Pro-amide, Pro, Gly, Ala, Val, Leu, Ile, Lys, Arg, Orn, Ser, Thr, CN, CONH 2 , COR′, SO 2 R′, CONR′R″, NHCOR′, OR′, or SO 2 NR′R″; wherein said optionally substituted heterocyclyl is optionally singly or doubly substituted with substituents independently selected from the group consisting of C 1 -C 6 alkyl, —C 1 -C 6 alkoxy, oxo, —OH, —Cl, —F, —NH 2 , —NO 2 , —CN, —COOH, and amidino; wherein R′ and R″ are each independently —H, C 1 -C 8 alkyl, aryl, heterocyclyl or R′ and R″ are combined to form a 4- to 8-membered ring, which ring is optionally substituted singly or doubly with substituents independently selected from the group consisting of C 1 -C 6 alkyl, —C 1 -C 6 alkoxy, —OH, —Cl, —F, —NH 2 , —NO 2 , —CN, —COOH and amidino; and R 2 is H, amidino, singly or doubly C 1 -C 6 alkyl-substituted amidino, —CN, —CONH 2 , —CONR′R″, —NHCOR′, —SO 2 NR′R″, or —COOH; or
(b) R 1 and R 2 taken together can form an optionally substituted 4- to 9-membered heterocyclic monocyclic or bicyclic ring moiety which is bonded to a single ring atom of the Y and Z-containing ring moiety; or
(c) R 1 and R 2 taken together with a single ring atom of the Y and Z-containing ring moiety can form an optionally substituted 4- to 8-membered heterocyclic ring moiety to form a spiro structure; or
(d) R 1 and R 2 taken together with two or more adjacent ring atoms of the Y and Z-containing ring moiety can form an optionally substituted 4- to 9-membered heterocyclic monocyclic or bicyclic ring moiety fused to the Y and Z-containing ring moiety;
wherein each of said optionally substituted 4- to 9-membered heterocyclic ring moieties comprising R 1 and R 2 is optionally singly or doubly substituted with substituents independently selected from the group consisting of C 1 -C 6 alkyl, —C 1 -C 6 alkoxy, optionally substituted phenyl, oxo, —OH, —Cl, —F, —NH 2 , —NO 2 , —CN, —COOH, and amidino;
provided that when the Y and Z-containing ring moiety is a six or seven membered ring comprising a single ring heteroatom and when one of Y and Z is C and the other of Y and Z is N, and e is zero, then R 1 is not —OH, and R 1 and R 2 are not both —H;
provided further that when the Y and Z-containing ring moiety is a six membered ring comprising two ring heteroatoms, both Y and Z are N, W is null, and —V e (R 1 )(R 2 ) is attached to Z, then —V e (R 1 )(R 2 ) is selected from the group consisting of amidino, C 1 -C 6 alkyl-substituted amidino, dihydroimidazole, —CH 2 COOH, and —CH 2 C(O)NH 2 ; and
lastly, provided that if the Y and Z-containing ring moiety is a six membered ring comprising an S or O ring heteroatom, or if the Y and Z-containing ring moiety is a six membered ring comprising two ring heteroatoms, wherein both Y and Z are N and W is null, or if the Y and Z-containing ring moiety is a six membered aromatic ring comprising a single ring heteroatom, which heteroatom is N, then, when e is zero, R 1 and R 2 are not both —H.
2. The method according to claim 1 , wherein G is
wherein p, q, r, s and t are each 1.
3. The method according to claim 1 , wherein G is
and L is a linker selected from the group consisting of ε-D-Lys, ε-Lys, δ-D-Orn, δ-Orn, 4-amino-4-carboxylic piperidine and (D-Lys-Gly lactam) 2 .
4. The method according to claim 1 , wherein W is null, Y is N and Z is C.
5. The method according to claim 1 , wherein the Y and Z-containing ring moiety is a six-membered saturated ring comprising a single ring heteroatom.
6. The method according to claim 1 , wherein Y and Z are both N and are the only ring heteroatoms in the Y and Z-containing ring moiety.
7. The method according to claim 1 , wherein e is zero.
8. The method according to claim 1 , wherein R 1 and R 2 taken together with one ring atom of the Y and Z-containing ring moiety comprise a 4- to 8-membered heterocyclic ring moiety which with the Y and Z-containing ring moiety forms a spiro structure and W is null.
9. The method according to claim 1 , wherein e is zero and R 1 and R 2 are bonded directly to the same ring atom.
10. The method according to claim 1 , wherein R 1 is H, OH, —NH 2 , —COOH, C 1 -C 3 alkyl, amidino, C 1 -C 3 alkyl-substituted amidino, dihydroimidazole, Pro, Pro amide, or CONH 2 and wherein R 2 is H, or —COOH.
11. The method according to claim 1 , wherein the moiety:
is selected from the group consisting of:
12. The method according to claim 1 , wherein the moiety:
is selected from the group consisting of:
13. The method according to claim 1 , wherein the synthetic peptide amide has a structure selected from the group consisting of:
1N,4N-bis-[D-Phe-D-Phe-D-Leu-(iPr)D-Orn]-4-amino-4-carboxylic piperidine,
1N,4N-bis-[D-Phe-D-Phe-D-Leu-D-Dap(Amidino)]-4-amino-4-carboxylic piperidine,
1N,4N-bis-(D-Phe-D-Phe-D-Leu-D-Nar)-4-amino-4-carboxylic piperidine,
and
14. The method according to claim 1 , wherein the moiety
is an optionally substituted 6- or 7-membered heterocyclic ring moiety wherein Y is nitrogen and Z is carbon, nitrogen, oxygen, sulfur, sulfoxide, or sulfonyl.
15. The method according to claim 1 , wherein the synthetic peptide amide is administered to the mammal in a pharmaceutically acceptable excipient or carrier.
16. The method according to claim 1 , comprising administering to the mammal a composition comprising an effective amount of the synthetic peptide amide by injection, infusion or by a pump.
17. The method according to claim 16 , wherein the administration is intravenous, subcutaneous, intramuscular, intraperitoneal, intra-articular or intraocular.
18. The method according to claim 1 , wherein the administration to the mammal is topical or local.
19. The method according to claim 18 , wherein the composition is administered intranasally, transdermally, intravaginally, intrarectally or by an intrapulmonary route.
20. The method according to claim 18 , wherein the composition is administered iontophoretically, or by a patch coated, diffused or impregnated with the synthetic peptide amide.
21. The method according to claim 18 , wherein the composition is administered locally in an implant.
22. The method according to claim 18 , wherein the composition is administered topically to a mucosal surface selected from the group consisting of a mouth, a esophagus, a larynx, a bronchus and a nasal passage.
23. The method according to claim 18 , wherein the composition is administered topically to a vagina, a rectum or an anus.
24. The method according to claim 18 , wherein the composition is administered in a sustained-release formulation.
25. The method according to claim 18 , wherein the composition is administered in a tablet, a capsule, an ointment, a liquid, a powder or a gum.
26. The method according to claim 1 , comprising administering the composition orally to the mammal.
27. The method according to claim 1 , wherein the mammal is a human.
28. The method according to claim 1 , wherein the disease or condition is pain.
29. A method of treating, inhibiting or preventing kappa opioid receptor associated pain, or of inhibiting or treating kappa opioid receptor associated pancreatitis or pruritis in a mammal, the method comprising administering to the mammal a composition comprising an effective amount of a synthetic peptide amide having the formula:
Xaa 1 -Xaa 2 -Xaa 3 -Xaa 4 -G
or a stereoisomer, mixture of stereoisomers, pharmaceutically acceptable salt, hydrate, acid salt hydrate, or N-oxide thereof, wherein:
Xaa 1 is independently selected from the group consisting of (A)(A′)D-Phe, (A)(A′)(α-Me)D-Phe, D-Tyr, D-Tic, D-tert-leucine, D-neopentylglycine, D-phenylglycine, D-homophenylalanine, and β-(E)D-Ala,
Xaa 2 is independently selected from the group consisting of (A)(A′)D-Phe, (A)(A′)(α-Me)D-Phe, D-1Nal, D-2Nal, D-Tyr, (E)D-Ala, and D-Trp;
Xaa 3 -Xaa 4 - is selected from the group consisting of D-Nle-(B) 2 D-Arg-, D-Leu-δ-(B) 2 α-(B′)D-Orn-, and (α-Me)D-Leu-δ(B) 2 -α(B′)D-Orn-;
wherein each (A) and each (A′) are phenyl ring substituents independently selected from the group consisting of —H, —F, —Cl, —NO 2 , —CH 3 , —CF 3 , —CN, —CONH 2 , and each (B) is independently selected from the group consisting of —H and C 1 -C 4 alkyl, and (B′) is —H or (α-Me); and wherein each (E) is independently selected from the group consisting of cyclobutyl, cyclopentyl, cyclohexyl, pyridyl, thienyl and thiazolyl;
G is
and the moiety
is an optionally substituted 4 to 8-membered heterocyclic ring moiety wherein all ring heteroatoms in said ring moiety are N; wherein Y and Z are each independently C or N; provided that when such ring moiety is a six, seven or eight-membered ring, Y and Z are separated by at least two ring atoms; and
provided that when such ring moiety has a single heteroatom which is N, then such ring moiety is non-aromatic;
wherein W is selected from the group consisting of:
null, provided that when W is null, Y is N;
—NH—(CH 2 ) b — with b equal to zero, 1, 2, 3, 4, 5, or 6; and
—NH—(CH 2 ) c —O— with c equal to 2, or 3;
wherein V is C 1 -C 6 alkyl, and e is zero or 1, wherein when e is zero, then V is null and, R 1 and R 2 are directly bonded to the same or different ring atoms;
wherein
(a) R 1 is —H, —OH, halo, CF 3 , —NH 2 , —COOH, C 1 -C 6 alkyl, amidino, C 1 -C 6 alkyl-substituted amidino, aryl, optionally substituted heterocyclyl, Pro-amide, Pro, Gly, Ala, Val, Leu, Ile, Lys, Arg, Orn, Ser, Thr, CN, CONH 2 , COR′, SO 2 R′, CONR′R″, NHCOR′, OR′, or SO 2 NR′R″; wherein said optionally substituted heterocyclyl is optionally singly or doubly substituted with substituents independently selected from the group consisting of C 1 -C 6 alkyl, —C 1 -C 6 alkoxy, oxo, —OH, —Cl, —F, —NH 2 , —NO 2 , —CN, —COOH, and amidino; wherein R′ and R″ are each independently —H, C 1 -C 8 alkyl, aryl, heterocyclyl or R′ and R″ are combined to form a 4- to 8-membered ring, which ring is optionally substituted singly or doubly with substituents independently selected from the group consisting of C 1 -C 6 alkyl, —C 1 -C 6 alkoxy, —OH, —Cl, —F, —NH 2 , —NO 2 , —CN, —COOH and amidino; and R 2 is H, amidino, singly or doubly C 1 -C 6 alkyl-substituted amidino, —CN, —CONH 2 , —CONR′R″, —NHCOR′, —SO 2 NR′R″, or —COOH; or
(b) R 1 and R 2 taken together can form an optionally substituted 4- to 9-membered heterocyclic monocyclic or bicyclic ring moiety which is bonded to a single ring atom of the Y and Z-containing ring moiety; or
(c) R 1 and R 2 taken together with a single ring atom of the Y and Z-containing ring moiety can form an optionally substituted 4- to 8-membered heterocyclic ring moiety to form a spiro structure; or
(d) R 1 and R 2 taken together with two or more adjacent ring atoms of the Y and Z-containing ring moiety can form an optionally substituted 4- to 9-membered heterocyclic monocyclic or bicyclic ring moiety fused to the Y and Z-containing ring moiety;
wherein each of said optionally substituted 4- to 9-membered heterocyclic ring moieties comprising R 1 and R 2 is optionally singly or doubly substituted with substituents independently selected from the group consisting of C 1 -C 6 alkyl, —C 1 -C 6 alkoxy, optionally substituted phenyl, oxo, —OH, —F, —NH 2 , —NO 2 , —CN, —COOH, and amidino;
provided that when the Y and Z-containing ring moiety is a six or seven membered ring comprising a single ring heteroatom and when one of Y and Z is C and the other of Y and Z is N, and e is zero, then R 1 is not —OH, and R 1 and R 2 are not both —H;
provided further that when the Y and Z-containing ring moiety is a six membered ring comprising two ring heteroatoms, both Y and Z are N, W is null, and —V e (R 1 )(R 2 ) is attached to Z, then —V e (R 1 )(R 2 ) is selected from the group consisting of amidino, C 1 -C 6 alkyl-substituted amidino, dihydroimidazole, —CH 2 COOH, and —CH 2 C(O)NH 2 ; and
and lastly, provided that if the Y and Z-containing ring moiety is a six membered ring comprising two ring heteroatoms, wherein both Y and Z are N and W is null, or if the Y and Z-containing ring moiety is a six membered aromatic ring comprising a single ring heteroatom, which heteroatom is N, then, when e is zero, R 1 and R 7 are not both —H.
30. The method according to claim 29 , wherein W is null, Y is N and Z is C.
31. The method according to claim 29 , wherein the Y and Z-containing ring moiety is a six-membered saturated ring comprising a single ring heteroatom.
32. The method according to claim 29 , wherein Y and Z are both N and are the only ring heteroatoms in the Y and Z-containing ring moiety.
33. The method according to claim 29 , wherein e is zero.
34. The method according to claim 29 , wherein R 1 and R 2 taken together with one ring atom of the Y and Z-containing ring moiety comprise a 4- to 8-membered heterocyclic ring moiety which with the Y and Z-containing ring moiety forms a spiro structure and W is null.
35. The method according to claim 29 , wherein e is zero and R 1 and R 2 are bonded directly to the same ring atom.
36. The method according to claim 29 , wherein R 1 is H, OH, —NH 2 , —COOH, C 1 -C 3 alkyl, amidino, C 1 -C 3 alkyl-substituted amidino, dihydroimidazole, Pro, Pro amide, or CONH 2 and wherein R 2 is H, or —COOH.
37. The method according to claim 29 , wherein the moiety:
is selected from the group consisting of:
38. The method according to claim 29 , wherein the moiety:
is selected from the group consisting of: